


<b>Name of Policy:</b> <u>Polypharmacy</u> <b>Policy Number:</b> 3364-160-SD-129 <b>Department:</b> Psychiatry <b>Approving Officer:</b> Chief Executive Officer - UTMC <b>Responsible Agent:</b> Chair/Medical Director Department of Psychiatry Administrative Director Department of Psychiatry <b>Scope:</b> OP-Clinic-Psychiatry	  <b>Effective Date:</b> 06/18/2024 Initial Effective Date: 07/2004			
<table style="width: 100%; border: none;"> <tr> <td style="width: 40%; border: none;"> <input type="checkbox"/> New policy proposal  <input type="checkbox"/> Major revision of existing policy         </td> <td style="width: 20%; border: none; text-align: center;"> <input checked="" type="checkbox"/> </td> <td style="width: 40%; border: none;">           Minor/technical revision of existing policy            Reaffirmation of existing policy         </td> </tr> </table>		<input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy	<input checked="" type="checkbox"/>	Minor/technical revision of existing policy Reaffirmation of existing policy
<input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy	<input checked="" type="checkbox"/>	Minor/technical revision of existing policy Reaffirmation of existing policy		

### (A) Policy Statement

The provider will attempt to minimize the number of psychotropic medications that patients use while fully treating the target symptoms that have been identified.

### (B) Purpose of Policy

To minimize the number of psychotropic medications prescribed to patients with severe and/or complicated psychiatric illness without neglecting full treatment of the target symptoms.

### (C) Procedure

1. The provider will be aware of the greater potential for side effects and drug interactions with an increasing number of medications especially if multiple agents in the same class are utilized, as well as the potential cost burden of using multiple medications.
2. The provider will discuss the potential side effects of using multiple psychotropic medications with the patient and/or guardian when deciding the best medication options.
3. The provider will obtain and document informed consent from patient and/or guardian regarding the use of prescribed psychotropic medications.

<b>Approved by:</b>  <div style="display: flex; justify-content: space-between; margin-bottom: 10px;"> <div style="width: 45%;"> <u>/s/</u>            Rick Swaine, CPA            Chief Executive Officer, UTMC         </div> <div style="width: 45%; text-align: center;"> <u>                    </u>            Date         </div> </div> <div style="display: flex; justify-content: space-between; margin-bottom: 10px;"> <div style="width: 45%;"> <u>/s/</u>            Robert Smith, MD, PhD            Chair, Department of Psychiatry         </div> <div style="width: 45%; text-align: center;"> <u>                    </u>            Date         </div> </div> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <u>/s/</u>            Stephanie Calmes, Ph.D., LPCC-S, LICDC-CS            Administrative Director, Department of Psychiatry         </div> <div style="width: 45%; text-align: center;"> <u>                    </u>            Date         </div> </div> <div style="margin-top: 10px;"> <i>Review/Revision Completed By:</i>  <i>Agency Administration</i> </div>	<b>Review/Revision Date:</b> 08/2005 08/2007 10/2/2010 03/04/2014 1/10/2017 09/21/2018 07/06/2021 06/18/2024  <hr/> <b>Next Review Date:</b> 06/18/2027
<b>Policies Superseded by This Policy:</b> ODMH-SD-129	